glp 1 shortage ending Compounding pharmacies to halt semaglutide sales May 22 FDA sets tirzepatide compounding deadlines

Any discussion of specific peptides or potential research findings is informational only and must not be interpreted as guidance for use in or on humans or animals

Centrally, GLP-1 receptor agonists modulate brain regions controlling appetite and energy expenditure

Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release)

Its multimodal mechanisms of action and excellent tolerability make it a promising candidate for adjunctive or standalone treatment in mood disorders